Dennis Brown

Medasystems, Inc. is a software development company based in Menlo Park, CA. Medasystems specializes in developing software that streamlines the handling of requests for experimental therapies from healthcare providers. The company's secure and GXP compliant application acts as a centralized environment, connecting physicians and pharmaceutical companies to facilitate patient access to investigational therapies. The platform streamlines physician inquiries to life science companies for investigational medicine, including expanded access or compassionate use, post-trial access, and investigator-initiated studies. Medasystems provides pharmaceutical manufacturers with software and tools to streamline expanded access or compassionate use requests, as well as the evaluation of IIS or IST proposals, and the management of post-trial access. Medasystems, Inc. was founded by Jeffrey Thibeault, Matthew Rosen, and John Langlands. Fiona Smythe has been the CEO of the company since 2021.

Azora Therapeutics, Inc. is a clinical stage biopharmaceutical company that develops novel small molecule chemical entities for the treatment of autoimmune and auto-inflammatory diseases. The company is based in Encino, CA. Azora Therapeutics was founded by Matthew Davidson and Julie Saiki, with Matthew Davidson serving as the CEO since incorporation.

National Brain Tumor Society, Inc. operates a foundation focused on brain tumor treatment. The company was founded by G. Bonnie Feldman in 2008 and is headquartered in Newton, MA.

Mountain View Pharmaceuticals, Inc. manufactures bio-pharmaceutical drugs. The American company was founded by Merry R. Sherman, Dennis M. Brown. Merry R. Sherman has been the CEO since incorporation.

Part of Kintara Therapeutics, Inc., Del Mar Pharmaceuticals (BC) Ltd. provides drug development services. The private company is based in Vancouver, Canada. The Canadian company was founded by William James Garner, Jeffrey A. Bacha, Dennis M. Brown. Jeffrey A. Bacha has been the CEO since incorporation. Del Mar Pharmaceuticals (BC was acquired by Kintara Therapeutics, Inc. on January 25, 2013 for $0.65 million.